In our study, we found an increase in Hb levels of 2.4 g/dL at 4 weeks and of 3.1 g/dL at 12 weeks, thus showing a good response to FCM treatment in CAG compared to that in IBD patients and superior in the majority of cases. The gene discussed is GSTM1; the disease is inflammatory bowel disease.